Gabriela Santana Oliveira

Gabriela Santana Oliveira

Auto-generated profile, based on publicly available information

Gabriela Santana Oliveira

Postgraduate Program in Pharmaceutical Services and Policies, Health Science Center, Federal University of Rio Grande do Norte , Natal, RN 59078-970

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2026 in Journal of Pharmaceutical Health Services Research
Verified
Journal Article
Closed access
GOGabriela Santana Oliveira
Gabriela Santana Oliveira
PBPriscilla Karilline Do Vale Bezerra
Priscilla Karilline Do Vale Bezerra
JCJéssica Escorel Chaves Cavalcanti
Jéssica Escorel Chaves Cavalcanti
LSLarissa Cândido Gomes da Silva
Larissa Cândido Gomes da Silva
SMSarah Dantas Viana Medeiros
Sarah Dantas Viana Medeiros
RMRand Randall Martins
Rand Randall Martins
Objectives: To evaluate the impact on clinical parameters and maternal-foetal outcomes of serious drug interactions in high-risk hospitalized pregnant women. Methods: A prospective cohort study including 571 pregnant women hospitalized between September 2019 and June 2022, with an average age of 30.6 years, mostly diagnosed with hypertensive syndromes (69.7%) and gestational diabetes (57.1%). Drug interactions were characterized daily through Lexicomp®, with monitoring of clinical parameters linked to their mechanisms of action. We used a multivariable logistic regression model with demographic and treatment variables to identify factors associated with drug interactions. In a second model, we analysed the impact of serious drug interactions on clinical outcomes, including maternal-foetal outcomes such as macrosomia, foetal tachycardia, amniotic fluid abnormalities, and prematurity. Key findings: We identified 203 pregnant women with one or more serious drug interactions (35.6%), and the risk factors were gestational age (adjusted odds ratio [AOR]: 0.96; 95% CI: 0.93–0.98), diagnosis of hypertension (AOR: 3.00; 95% CI: 2.49–6.41), number of medications (AOR: 1.09; 95% CI: 1.03–1.15), and length of hospitalization (AOR: 1.18; 95% CI: 1.12–1.26). Dipyrone and acetylsalicylic acid co-administration increased systolic blood pressure (AOR: 2.12; 95% CI: 1.01–4.47), while scopolamine and levomepromazine resulted in greater drowsiness (AOR: 5.38; 95% CI: 1.66–17.40) and a temperature increase (AOR: 5.96; 95% CI: 1.23–28.98). Conclusion: High-risk pregnant women of lower gestational age or with hypertensive syndromes are exposed to severe drug interactions, yet these interactions show limited clinical impact and do not significantly affect maternal-foetal outcomes.